MRK

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck & Company, Inc. stock is ending 2025 on a strong note. On December 24, 2025, shares of Merck (MRK) pushed to a fresh 12‑month high around the $106 level, extending a powerful late‑year rally that has put the pharma

24 December 2025

Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Dateline: Dec. 22, 2025 (pre-market) — Merck & Co., Inc. (NYSE: MRK) enters the new week with a fast-moving mix of policy headlines, FDA acceleration news, and shifting analyst sentiment—all landing on top of the company’s longer-running story: strong near-term

22 December 2025

Financial News · Investing · Market Analysis · NYSE:MRK · Pharma Stocks · Stock Market

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in

12 December 2025

Financial Forecasts · Investment Analysis · NYSE:MRK · Patent News · Pharmaceuticals · Stock Market

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a

8 December 2025

Company News · Financial Analysis · Investing · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt

7 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck & Co., Inc. (NYSE: MRK) heads into the Monday, December 1, 2025 market open riding one of the strongest monthly rallies in the S&P 500, powered by upbeat earnings, dividend growth and a string of bullish analyst calls focused

30 November 2025

Earnings Preview · Investment Strategies · Market Outlook · NYSE:MRK · Pharma Industry · Stock Analysis

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As

29 November 2025

Company Updates · Healthcare Stocks · Investment Insights · NYSE:MRK · Pharmaceutical Industry · Stock Market News

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck & Co., Inc. (NYSE: MRK) spent Wednesday trading just below fresh 52‑week highs, as Wall Street continues to digest a powerful mix of positive drug news, upbeat earnings, and a wave of analyst upgrades and institutional buying. Merck stock

26 November 2025

Analyst Ratings · Financial News · Investment · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Company Upgrades · FDA Approval · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within

24 November 2025

Analyst Ratings · Company Earnings · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

November 18, 2025 — Merck & Co. (NYSE: MRK) is trading higher today after the company reported new mid‑stage data for its cardiopulmonary medicine Winrevair (sotatercept‑csrk), fueling optimism about growth beyond Keytruda and adding momentum to last week’s acquisition of

18 November 2025

Clinical Trials · Flu Treatments · Merck News · NYSE:MRK · Pharma Partnerships · Stock Updates